STAT

JUNE 7, 2024

When large swaths of the East Coast were shrouded in wildfire smoke last summer, scientists in California grimly joked that maybe, finally, power brokers in New York and Washington, D.C. would be spurred to act on the burning issue that has long plagued the West Coast. Despite wildfire seasons that regularly burn hundreds of thousands of acres in California alone each year, researchers know relatively little about the long-term effects of chronic wildfire smoke on the body , and funding to reduc

361

361

BioPharma Dive

JUNE 7, 2024

A vote against MDMA-assisted therapy set back a high-profile treatment. Proponents argue the panel offered few solutions to longstanding problems, making the path forward unclear.

130

130

STAT

JUNE 7, 2024

The Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50. Arexvy, which was the first RSV vaccine approved , now becomes the first to be available to adults under the age of 60 who are not pregnant. Prior to this FDA decision, Arexvy was licensed for use in people 60 and older.

Vaccines 360

Vaccines 360

European Pharmaceutical Review

JUNE 7, 2024

Friend or foe? Pharmaceutical companies ask themselves this question before embracing the latest technologies because every innovation comes with both opportunities and risks. Today, technological advancements in artificial intelligence (AI), machine learning (ML), digitalisation, and robotic manufacturing automation solutions stand to revolutionise R&D, clinical trials, and manufacturing in the pharmaceutical industry.

Health and Personal Care Stores 113

Health and Personal Care Stores Pharmaceutical Companies Pharmaceutical Companies Drug Development 113

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

JUNE 7, 2024

For many Americans, health care means going to a local primary care office. But the vast majority of clinical research is conducted inside the walls of large, specialized academic health centers. Millions of patients are left out of those studies, which often fail to capture the population in all its diversity. Now, for the first time, the National Institutes of Health is investing in the creation of a national primary care research network to try to address this issue.

326

326

European Pharmaceutical Review

JUNE 7, 2024

New sub-analysis data from a Phase II clinical trial show that after 48 weeks of survodutide treatment, 83.0 percent of adults with liver fibrosis achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH). This is compared to 18.2 percent with placebo. With its novel mechanism of action, the glucagon/GLP-1 receptor dual agonist is the first to show this level of fibrosis benefit in a Phase II MASH trial following 48 weeks of treatment, according

111

111

European Pharmaceutical Review

JUNE 7, 2024

The first telomerase inhibitor has been approved by the US Food and Drug Administration (FDA). RYTELO ( imetelstat ) is authorised for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anaemia. The first-in-class oligonucleotide telomerase inhibitor is indicated for these patients who need four or more red blood cell units over eight weeks, who are unresponsive to or ineligible for erythropoiesis-stimulating agents (ESA).

105

105

STAT

JUNE 7, 2024

Good morning, Jason Mast here filling in for Ed. Today, we’re sipping a hot cup of caffeinated black, while mulling the rise and fall and, apparently (!), rise again of Luckin Coffee, a chain whose cashless kiosks and discount lattes were once seen as China’s answer to Starbucks, before allegations emerged of widespread accounting fraud.

Documentation 256

Documentation 256

PharmaVoice

JUNE 7, 2024

How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.

100

100

STAT

JUNE 7, 2024

Weight loss treatments have the potential to revolutionize health care in rich countries. They are driving a race among drugmakers for a slice of a market that could exceed $100 billion by 2030. But little thought has apparently been given to helping people in low- and middle-income countries, where obesity rates are soaring despite poor nutrition. Without decisive action to develop fair access plans to these drugs for people living in poorer countries, there is a real danger that a significant

250

250

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

pharmaphorum

JUNE 7, 2024

Explore how commercialisation is the new frontier for digital innovation in the pharmaceutical industry, with a focus on GLP-1 drugs, digital strategies, and reducing patient acquisition costs.

111

111

STAT

JUNE 7, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Well, this wraps up one of the most eventful weeks of the biotech year — ASCO, followed by BIO. Anyone else as zonked as I am? Today, we discuss the impact that the BIOSECURE Act is already having on the industry, preview what FDA reviewers want to know about donanemab, and more.

Drug Pricing 253

Drug Pricing Drug Development 253

Express Pharma

JUNE 7, 2024

The telomerase inhibitor, will be used for the treatment in Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia Geron Corporation biopharma company, announced the U.S. Food and Drug Administration (FDA) approval for RYTELO (imetelstat). The drug is for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have

Clinic Management 105

Clinic Management 105

STAT

JUNE 7, 2024

Philanthropists and foundations like the one I work for take a lot of calculated risks. We invest in research, advocacy, strategic communications, technical assistance, and many other activities, hoping they will help us advance our strategic priorities. We evaluate our efforts whenever we can, but many defy measurement — assessing the impact of our work is a persistent challenge.

Communication 241

Communication 241

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Pharmaceutical Business Review

JUNE 7, 2024

The investment is managed by the funds of Permira and is expected to close by the fourth quarter of 2024, subject to necessary approvals and conditions. The companies did not disclose the financial terms of the deal. PharmaCord, known for its role as a commercialisation partner for life sciences organisations, focuses on enhancing the patient experience with specialty medications.

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceutical Companies 97

STAT

JUNE 7, 2024

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.

212

212

The Pharmacist

JUNE 7, 2024

The National Institute for Health and Care Excellence (NICE) has recommended that tirzepatide be prescribed by NHS primary care services, in draft guidance currently out for consultation. The weekly injection has been recommended alongside diet and exercise advice for people with a BMI of at least 35kg/m2 and one weight-related comorbidty with lower thresholds for […] The post NICE recommends tirzepatide for NHS primary care appeared first on The Pharmacist.

94

94

pharmaphorum

JUNE 7, 2024

UK group Cycle Pharma has made an unsolicited takeover bid to buy Vanda Pharma, which is already fending off an overture from Future Pak.

112

112

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

Express Pharma

JUNE 7, 2024

The listing follows the strategic demerger of the scientific business from Borosil, completed in December’ 2023 Borosil Scientific, announced its successful listing on both Stock Exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). The milestone was marked with the ringing of the opening bell at BSE in the presence of Pradeep Kheruka, Promotor of Borosil Group, Vinayak Patankar, Whole-time Director and Chief Executive Officer and Kewal Handa, Chairman and Independent

Packaging 98

Packaging 98

pharmaphorum

JUNE 7, 2024

Nestle Health Science bids to take control of Seres Therapeutics’ oral microbiome product Vowst for preventing C. diff infections.

112

112

Pharma Times

JUNE 7, 2024

Phase 2 trial reveals significant improvement in MASH patients

128

128

pharmaphorum

JUNE 7, 2024

Learn how building resilience can positively impact cancer trials in the field of oncology. Learn more about CancerEngage.

110

110

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharma Times

JUNE 7, 2024

Early-stage endometriosis now visible through non-invasive imaging

113

113

pharmaphorum

JUNE 7, 2024

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo. The US regulator has cleared Rytelo (imetelstat) for adults with lower-risk MDS who have transfusion-dependent anaemia and have stopped responding to or cannot be treated with erythropoiesis-stimulating agents (ESAs) like erythropoietin (EPO).

88

88

BioPharma Dive

JUNE 7, 2024

After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.

64

64

pharmaphorum

JUNE 7, 2024

Discover how compounding pharmacies use genetic information to create precision medications tailored to individual allergies. Learn how personalised treatments can benefit you.

Compounding Pharmacies 69

Compounding Pharmacies Compounding 69

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Express Pharma

JUNE 7, 2024

Climate change-related exacerbations of MS will necessitate the development of more effective DMTs as disease flare ups become more frequent with fluctuating temperatures A June 2024 literature review, published in the Lancet Neurology, by Sisodya and colleagues revealed that climate change has the potential to intensify multiple sclerosis (MS) symptoms.

Compounding 77

Compounding 77

pharmaphorum

JUNE 7, 2024

Join us for an exclusive interview with Dr Suzanne Trudel at ASCO 2024, where she will share insights on the latest advancements in cancer research and treatment. Stay tuned for this exciting conversation!

72

72

Pharmafile

JUNE 7, 2024

Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m. The post Nuclera gains £1.14m funding from Innovate UK appeared first on Pharmafile.

59

59

Pharmaceutical Commerce

JUNE 7, 2024

By marrying real-world evidence and AI, pharma stakeholders can identify new opportunities to tailor interventions in a way that is most impactful to patients—helping them overcome roadblocks in initiating and maintaining therapy.

59

59

Pharmafile

JUNE 7, 2024

Geron Corporation has announced that the US Food and Drug Administration (FDA) has approved Rytelo (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anaemia who require at least four red blood cell units over eight weeks and who have not responded, or lost response to, or are ineligible for erythtopoiesus-stimulating agents (ESA).

59

59